Related Experiment Video
Updated: Aug 17, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Perspectives on novel therapies for bronchial carcinoma
Fiona Blackhall1, Pavlos I Papakotoulas, Sarah Danson
1Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK. Fiona.Blackhall@christie-tr.nwest.nhs.uk
Abstract:
Improvements in conventional cytotoxic treatment have probably reached a plateau for the treatment of lung cancer; therefore, new treatment strategies that are based on a better understanding of tumour biology are required. Some progress has been made for non-small cell lung cancer, in which erlotinib (Tarceva, OSI-774; Genentech), an epidermal growth factor receptor antagonist, has demonstrated a significant clinical benefit in a Phase III randomised trial, and has been licensed for second- or third-line treatment. Other therapies under investigation include angiogenesis inhibitors, COX-2 inhibitors, retinoids, farnesyl transferase inhibitors, Bcl-2 inhibitors and c-Kit antagonists. In this article the recent and ongoing Phase II and III trials of these therapies in lung cancer are summarised, and the prospects for their further clinical development are discussed.
Insights
New lung cancer treatments are needed as cytotoxic therapies plateau. Novel strategies targeting tumor biology, including epidermal growth factor receptor antagonists and angiogenesis inhibitors, show promise in clinical trials.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Conventional cytotoxic treatments for lung cancer have reached a therapeutic plateau.
- A deeper understanding of tumor biology necessitates novel treatment strategies for lung cancer.
- Targeted therapies offer new avenues for non-small cell lung cancer (NSCLC) treatment.
Purpose of the Study:
- To summarize recent and ongoing Phase II and III clinical trials of novel therapies for lung cancer.
- To discuss the future clinical development prospects of these emerging lung cancer treatments.
Main Methods:
- Review of recent and ongoing Phase II and III clinical trials.
- Analysis of emerging targeted therapies including epidermal growth factor receptor antagonists, angiogenesis inhibitors, and others.
- Discussion of clinical benefits and development pathways.
Main Results:
- Erlotinib (Tarceva), an epidermal growth factor receptor antagonist, shows significant clinical benefit in NSCLC Phase III trials, approved for second- or third-line treatment.
- Investigational therapies include angiogenesis inhibitors, COX-2 inhibitors, retinoids, farnesyl transferase inhibitors, Bcl-2 inhibitors, and c-Kit antagonists.
- These novel agents are under evaluation in Phase II and III trials for lung cancer.
Conclusions:
- Novel targeted therapies demonstrate potential to improve lung cancer treatment outcomes beyond conventional cytotoxic approaches.
- Further clinical development of these agents is crucial for advancing lung cancer care.
- Personalized medicine based on tumor biology is key for future lung cancer therapy.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...